· PC
· PK
· PD
|
Propranolol |
Esmolol |
Structure |
Racemic |
Achiral |
|
Propranolol |
Esmolol |
Admin |
· IV bolus 1-2mg slowly · PO 40mg bd starting dose |
IV bolus 0.5mg/kg IV infusion 0.05-2mcg/kg/min |
Time course |
· Onset 2-10 mins (IV) · Duration 10-30 mins (IV) |
· Onset 1-2 mins · Duration 5 mins |
Absorption |
· Oral bioav 30% |
· Oral bioav 0% (IV only) |
Distribution |
· Plasma protein binding 95% · VD 3.5L/kg · High lipid solubility · Crosses blood-brain barrier effectively |
· Plasma protein binding 60% · VD 3.5L/kg · Moderate lipid solubility |
Metabolism |
· Hepatic oxidative deamination then dealkylation or glucuronidation · Active 4-OH metabolite · t1/2β 3 hours |
· RBC esterase to acid and alcohol; acid is weak β-blocker · Cl 300mL/kg/min · t1/2β 10 mins |
Excretion |
· <1% unchanged. |
· 1% unchanged |
|
Propranolol |
Esmolol |
Receptor effects |
S-propranolol: · β1 β2 non-selective · Membrane stabilizing activity (MSA) · No intrinsic sympathomimetic activity (ISA) R-propranolol: · Inhibit peripheral conversion T4->T3 (inhibits deodinase) |
· β1 selective · No membrane-stabilising activity · No MSA · No ISA |
Indications |
· Angina · HOCM · Thyrotoxicosis · Anxiety · Tremor |
· Intra-op hypertension · Ablate pressor response to laryngoscopy |
Side effects and toxicity |
· CNS: drowsiness, fatigue, depression, insomnia, nightmares · CVS: AV block, worsen acute LV failure, worsen peripheral vascular disease · Resp: bronchoconstriction (↑risk if asthma) · Metabolic: ↓autonomic response to hypoglycaemia, ↑risk T2DM · Other: hair loss · MSA toxicity: as for local anaesthetic toxicity o CNS: excitation (seizures) then inhibition (coma) o CVS: hypotension, arrhythmia, arrest |
· Similar · Minimal CNS effects · No MSA effects · Long term effects not relevant – used for short periods in critical care only |
Feedback welcome at ketaminenightmares@gmail.com